All In Biotech

Drug Trial Radar · NCT06795412

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Apr 15, 2025

Primary completion

Dec 6, 2027

Study completion Dec 6, 2027

Sponsor

Lead sponsor
Pyxis Oncology, IncIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jan 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • PYX-201Drug

    Intravenous (IV) infusion.

  • pembrolizumabDrug

    IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants who Experience a Dose-Limiting Toxicity (DLT)Time frame: Day 1 to Day 21
  2. Number of Participants who Experience an Adverse Event (AE)Time frame: Up to approximately 2 years
  3. Number of Participants who Experience Clinically Significant Changes in Clinical Laboratory ParametersTime frame: Up to approximately 2 years
  4. Number of Participants who Experience Clinically Significant Changes in Vital SignsTime frame: Up to approximately 2 years
  5. Number of Participants who Experience Clinically Significant Changes in electrocardiogram (ECG) ParametersTime frame: Up to approximately 2 years

Locations

22 sites in 3 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    San Diego, California · Recruiting

  • Sarcoma Oncology Center

    Santa Monica, California · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Stephenson Cancer Center - University of Oklahoma

    Oklahoma City, Oklahoma · Recruiting

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • University of Texas - M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology Houston

    Houston, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Hopital Saint - Andre - CHU de Bordeaux

    Bordeaux, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Hôpital de la Timone

    Marseille, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain · Recruiting

  • START Madrid - Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Clínico Universitario de Valencia

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.